- Home
- HRMY vs KSS Comparison
HRMY vs KSS Comparison
Compare HRMY & KSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | KSS |
|---|---|---|
| Founded | 2017 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2020 | 1992 |
Fundamental Metrics
Financial Performance| Metric | HRMY | KSS |
|---|---|---|
| Price | $36.78 | $17.76 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 8 | 14 |
| Target Price | ★ $49.75 | $16.08 |
| AVG Volume (30 Days) | 615.1K | ★ 3.3M |
| Earning Date | 02-24-2026 | 03-10-2026 |
| Dividend Yield | N/A | ★ 2.79% |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | 1.73 |
| Revenue | $825,944,000.00 | ★ $15,751,000,000.00 |
| Revenue This Year | $23.29 | N/A |
| Revenue Next Year | $15.98 | N/A |
| P/E Ratio | $11.58 | ★ $10.35 |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $25.52 | $6.04 |
| 52 Week High | $40.93 | $25.22 |
Technical Indicators
Market Signals| Indicator | HRMY | KSS |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 36.05 |
| Support Level | $35.16 | $17.67 |
| Resistance Level | $37.08 | $19.46 |
| Average True Range (ATR) | 1.43 | 1.12 |
| MACD | -0.21 | -0.41 |
| Stochastic Oscillator | 43.22 | 2.80 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About KSS Kohl's Corporation
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.